The KOSPI and KOSDAQ recaptured the 2600 and 900 levels side by side.

Reporter Kim Jisun / approved : 2023-08-10 03:38:11
  • -
  • +
  • 인쇄
 

 

[Alpha Biz=(Chicago) Reporter Kim Jisun] KOSPI and KOSDAQ, which overcame the impact of the US credit rating downgrade, recaptured the 2,600 and 900 levels side by side.

Foreign investors, who had recently maintained their selling trend, continued to buy together, leading the index to rise.

On the 9th, the KOSPI index rose 31.14 points (1.21%) from the previous trading day to 2605.12. Net buying by foreigners (KRW 355.4 billion) boosted the index. On the other hand, institutions and individuals sold a net 292.4 billion won and 87.7 billion won, respectively.

Foreigners showed net buying in both the present and future markets. Foreigners net bought 6491 contracts on the index futures market. Individuals and institutions sold a net 1751 contracts and 5771 contracts respectively.

By industry, medicine and medical precision were strong in the 3% range. The biggest rise was Aprogen BioLogics, thanks to the rise of bio shares led by pharmaceutical company Eli Lilly on the previous day (local time). Dong-A ST also rose 26.61%.

Electricity and electronics were strong in the 2% range. Manufacturing followed with a 1% rise. Machinery, non-metal minerals, distribution, transportation equipment, service and telecommunications closed in an upward trend. Insurance, securities, food and beverage, finance and transportation warehouses remained flat.

The top market cap stocks all rose except SK Hynix, which fell 0.08%, and POSCO Holdings, which finished flat. In particular, bio shares Samsung BioLogics and Celltrion rose 1.01% and 4.66%, respectively. LG Energy Solutions rose 5.33%. Hyundai Mobis, LG Chem and NAVER finished strong in the 2% range. Samsung Electronics rose 1.92 percent.

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

주요기사

Civic Groups File Complaint Against Baemin and Coupang Eats Over Alleged Misleading “One-Person Free Delivery” Promotions2025.09.19
KT Confirms Additional Victims in Unauthorized Micro-Payment Case, Faces Criticism Over Initial Response2025.09.19
KFTC Grants Conditional Approval for Joint Venture Between Shinsegae Group and Alibaba Group2025.09.19
Supreme Court Rules in Favor of NTS on U.S. Unregistered Patent Royalties2025.09.19
Korea Zinc to Cancel All Treasury Shares by Year-End, Targeting Shareholder Return Ratio Above 200%2025.09.19
뉴스댓글 >

HEADLINE

건강이 보이는 대표 K Medical 뉴스

PHOTO

많이 본 기사